14 Best Small Cap Stocks to Buy Right Now

6. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Market Capitalization: $2 Billion

Number of Hedge Fund Holders: 32

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the best small cap stocks to buy right now. On September 3, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) submitted a supplemental New Drug Application to the U.S. FDA to expand the indication of ZORYVE.

Arcutis Biotherapeutics’ application for ZORYVE cream 0.3% is developed for the treatment of plaque psoriasis in children down to the age of two. Arcutis’ cream is uniquely formulated to be effective, safe, and well-tolerated for all areas of the body. ZORYVE can be used on sensitive areas such as intertriginous skin, where plaque psoriasis often presents in children.

“Today, there are very limited FDA-approved treatment options for plaque psoriasis for children under 6, who often present with disease on sensitive skin such as the face and intertriginous areas. There is a significant unmet need for non-steroidal options that can effectively treat plaque psoriasis over the long term. If approved, investigational ZORYVE cream could be an important first-line treatment option for children as young as age two,” said Adelaide Hebert, MD, professor and chief of pediatric dermatology at UTHealth Houston.

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor. It would become an alternative to topical steroids and vitamin-D analogs, offering an important alternative for patients. So far, the results from the long-term study indicate consistent favorable safety and tolerability along with efficacy across the age ranges studied.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company that is engaged in developing and commercializing treatments for dermatological diseases.